The Medtech Company THERACLION Obtains €8.5 Million In R&D Funding From OSEO (Medical News Today) PDF Print

Theraclion, the only medtech company in the world developing an innovative technology for the treatment of hyperparathyroidism1, today announced that it has been granted €8.5 million in R&D funding by OSEO (the French state innovation agency) as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy.

read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.